Difference between revisions of "Pegfilgrastim-cbqv (Udenyca)"
m (Text replacement - "[[Media:" to "[[File:") |
Warner-admin (talk | contribs) m (Text replacement - "‚" to ",") |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF), biosimilar of pegfilgrastim. Binds to cell surface receptors on hematopoietic cells and stimulates | + | Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF), biosimilar of pegfilgrastim. Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation.<ref name="insert">[https://udenyca.com/wp-content/pdfs/udenyca-pi.pdf Pegfilgrastim-cbqv (Udenyca) package insert]</ref><ref>[[:File:Pegfilgrastim-cbqv.pdf| Pegfilgrastim-cbqv (Udenyca) package insert (locally hosted backup)]]</ref><ref>[https://udenyca.com/ Udenyca manufacturer's website]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *11 | + | *2018-11-02: Approved to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia. |
==Also known as== | ==Also known as== | ||
| − | + | *'''Brand names:''' Udenyca | |
| − | *'''Brand names:''' | ||
==References== | ==References== | ||
Latest revision as of 17:53, 1 August 2023
General information
Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF), biosimilar of pegfilgrastim. Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation.[1][2][3]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
History of changes in FDA indication
- 2018-11-02: Approved to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.
Also known as
- Brand names: Udenyca